Full Press Release Details
ASX Market Announcements ASX Limited
Stock Exchange Centre 20 Bridge Street
RESULTS OF ANNUAL GENERAL MEETING
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the attached document provides details of the proxies received and the manner in which votes were cast for each resolution.
This announcement was authorised for release by the Company Secretary.
FOR FURTHER INFORMATION PLEASE CONTACT:
Ms Suzanne Irwin Company Secretary
About Bionomics Limited
Bionomics Limited (ASX: BNO, Nasdaq: BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the 7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.
Bionomics Limited | 200 Greenhill Road, Eastwood, South Australia, +61 8 8150 7400, ABN: 53 075 582 740
Tuesday, 21 February 2023
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
| Resolution details | Instructions given to validly appointed proxies (as at proxy close) | Number of votes cast on the poll (where applicable) | Resolution Result | ||||||
| Resolution | Resolution Type | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried |
| 1. Issue of Options to Dr Papapetropoulos | Ordinary | 319,929,841 90.50% | 32,120,106 9.09% | 1,452,010 0.41% | 427,437 - | 321,381,851 90.91% | 32,120,106 9.09% | 427,437 - | Carried |
| 2. Issue of Options to Dr De Souza | Ordinary | 318,690,124 90.23% | 33,050,348 9.36% | 1,452,010 0.41% | 736,912 - | 320,142,134 90.64% | 33,050,348 9.36% | 736,912 - | Carried |
| 3. Termination Benefits to Dr Papapetropoulos | Ordinary | 322,245,358 91.22% | 29,708,110 8.41% | 1,331,032 0.37% | 644,894 - | 323,576,390 91.59% | 29,708,110 8.41% | 644,894 | Carried |
| 4. Ratify prior issue of 115,384,680 shares | Ordinary | 189,779,948 96.75% | 2,002,072 1.02% | 4,370,829 2.23% | 157,776,545 - | 194,150,777 98.98% | 2,002,072 1.02% | 157,776,545 | Carried |
| * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. |